Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines
暂无分享,去创建一个
B. Hendriks | J. Fitzgerald | Helen Lee | D. Kirpotin | T. Wickham | M. Ventura | Nicholas Bernards | Jinzi Zheng | R. D. de Souza | D. Gaddy | Daniel F. Gaddy
[1] Karen Campbell,et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[2] R. Korn,et al. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.
[3] Zahi A. Fayad,et al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy , 2016, Nature Communications.
[4] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[5] Hiroshi Maeda,et al. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. , 2015, Advanced drug delivery reviews.
[6] U. Nielsen,et al. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302) , 2015, Molecular Cancer Therapeutics.
[7] Andreas Kjær,et al. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. , 2015, ACS nano.
[8] B. Hendriks,et al. Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates , 2015, EJNMMI Research.
[9] B. Hendriks,et al. A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[10] U. Nielsen,et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. , 2014, Cancer research.
[11] K. Greish,et al. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect , 2014, International journal of nanomedicine.
[12] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[13] U. Nielsen,et al. Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors , 2012, CPT: pharmacometrics & systems pharmacology.
[14] U. Nielsen,et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. , 2012, Toxicology and applied pharmacology.
[15] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[16] R. Bellamkonda,et al. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. , 2009, Radiology.
[17] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[18] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[19] John W. Park,et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.
[20] Raymond C Boston,et al. A modified logistic model to describe gadolinium kinetics in breast tumors. , 2004, Magnetic resonance imaging.
[21] R. Vile,et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[23] P M Carpenter,et al. Characterization of N‐ethyl‐N‐nitrosourea‐induced malignant and benign breast tumors in rats by using three MR contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.
[24] D M Shames,et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.
[25] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[26] R K Jain,et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.
[27] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.